Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Despite the impressive results of autologous CAR-T cell therapy in refractory B lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost-effective approach with no signs of severe toxicities as described for CAR-T cells. Permanently scrutinized for its efficacy, recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Valeri, Antonio, García-Ortiz, Almudena, Castellano, Eva, Córdoba, Laura, Maroto-Martín, Elena, Encinas, Jessica, Leivas, Alejandra, Río, Paula, Martínez-López, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381932/
https://www.ncbi.nlm.nih.gov/pubmed/35990652
http://dx.doi.org/10.3389/fimmu.2022.953849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381932/
https://www.ncbi.nlm.nih.gov/pubmed/35990652
http://dx.doi.org/10.3389/fimmu.2022.953849

Ejemplares similares